We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for Retifanlimab (Specialised Therapeutics Alim Pty Ltd)
Active ingredients
Retifanlimab
Date of review outcome
Lapse date
Type
Priority review
Indication
In combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC)
Therapeutic area
Oncology